<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081770</url>
  </required_header>
  <id_info>
    <org_study_id>P03471</org_study_id>
    <secondary_id>2552898</secondary_id>
    <nct_id>NCT00081770</nct_id>
  </id_info>
  <brief_title>Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)</brief_title>
  <official_title>Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to compare the safety and efficacy of the following three treatment regimens
      in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1)
      PegIntron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2)
      PegIntron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3)
      PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PegIntron Dose will be administered once weekly subcutaneously on the same day of the week:

      Screening 2 Weight 40-50 kg Volume to Inject (mL) 0.22; Screening 2 Weight 51-60 kg Volume to
      Inject (mL) 0.28; Screening 2 Weight 61-75 kg Volume to Inject (mL) 0.33; Screening 2 Weight
      76-85 kg Volume to Inject (mL) 0.41; Screening 2 Weight 86-104 kg Volume to Inject (mL) 0.48;
      Screening 2 Weight 105-125 kg Volume to Inject (mL) 0.58 from two vials

      REBETOL Dosage (for Use With PegIntron):

      Screening 2 Weight 40-65 kg Daily Dose 800 mg; Screening 2 Weight &gt;65-85 kg Daily Dose 1000
      mg; Screening 2 Weight &gt;85-105 kg Daily Dose 1200 mg; Screening 2 Weight &gt;105-125 kg Daily
      Dose 1400 mg

      The PEGASYS dose of 1 mL (180 µg) will be administered once weekly subcutaneously on the same
      day of the week

      COPEGUS Dosage (for Use With PEGASYS):

      Screening 2 Weight &lt;75 kg Daily Dose 1000 mg; Screening 2 Weight &gt; or = 75 kg Daily Dose
      1200mg

      NOTE: Double Blind for PegIntron; Open Label for REBETOL, PEGASYS and COPEGUS

      NOTE: REBETOL is the Schering-Plough brand name for ribavirin. COPEGUS is the Hoffman-La
      Roche brand name for ribavirin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response (SVR) Rate</measure>
    <time_frame>Assessed at the end of a 24-week post-treatment follow-up</time_frame>
    <description>SVR rate is the percentage of participants with undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at the end of the 24-week post-treatment follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Log Viral Load at Treatment Week 4</measure>
    <time_frame>Assessed at Baseline and Treatment Week 4</time_frame>
    <description>The difference between viral load levels in the blood at the start of the study and Treatment Week 4, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response Rate at Treatment Week 12</measure>
    <time_frame>Assessed at Treatment Week 12</time_frame>
    <description>Percentage of participants with undetectable hepatitis C RNA (HCV-RNA) at Treatment Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Log Viral Load at Treatment Week 2</measure>
    <time_frame>Assessed at Baseline and Treatment Week 2</time_frame>
    <description>The difference between viral load levels in the blood at the start of the study and Treatment Week 2, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4469</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>PegIntron 1.5 ug/kg/wk plus REBETOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PegIntron 1.0 ug/kg/wk plus REBETOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEGASYS 180 ug/wk Plus COPEGUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (peginterferon alfa-2b; SCH 54031)</intervention_name>
    <description>1.5 ug/kg/week subcutaneously (SC) for 48 weeks</description>
    <arm_group_label>PegIntron 1.5 ug/kg/wk plus REBETOL</arm_group_label>
    <other_name>PegIntron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (peginterferon alfa-2b; SCH 54031)</intervention_name>
    <description>1.0 ug/kg/week SC for 48 weeks</description>
    <arm_group_label>PegIntron 1.0 ug/kg/wk plus REBETOL</arm_group_label>
    <other_name>PegIntron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REBETOL (ribavirin; SCH 18908)</intervention_name>
    <description>weight based dose 800-1400 mg/day orally (PO) for 48 weeks</description>
    <arm_group_label>PegIntron 1.5 ug/kg/wk plus REBETOL</arm_group_label>
    <arm_group_label>PegIntron 1.0 ug/kg/wk plus REBETOL</arm_group_label>
    <other_name>REBETOL [the Schering-Plough brand name for ribavirin]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGASYS (peginterferon alfa-2a)</intervention_name>
    <description>180 ug/week SC administered for 48 weeks</description>
    <arm_group_label>PEGASYS 180 ug/wk Plus COPEGUS</arm_group_label>
    <other_name>PEGASYS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COPEGUS (ribavirin)</intervention_name>
    <description>1000-1200 mg/day PO for 48 weeks</description>
    <arm_group_label>PEGASYS 180 ug/wk Plus COPEGUS</arm_group_label>
    <other_name>COPEGUS [the Hoffman-La Roche brand name for ribavirin]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Previously untreated adults with chronic hepatitis C (hepatitis C virus ribonucleic
             acid [HCV RNA] quantitative polymerase chain reaction [qPCR] plasma positive)

          -  Individuals with HCV genotype 1 (mixed 1a/1b is acceptable)

          -  Compensated liver disease

          -  Pretreatment liver biopsy slides available

          -  Adults aged 18-70

          -  Individuals weighing 88-275 pounds (40-125 kg)

          -  Free from substance abuse for past 2 years

          -  Those suffering from diabetes and/or hypertension must have normal eye exams and
             retinal photographs (these will be done as part of the study before hepatitis C
             treatment is given)

          -  Patients and partners of patients willing to use adequate contraception during the
             course of the study

          -  Hematology laboratory results of:

               -  Hemoglobin (HGB) ≥ 12 g/dL for females or ≥ 13g/dL for males

               -  White Blood Cell Count (WBC) ≥ 3,000/mm^3

               -  Neutrophils ≥ 1,500/mm^3

               -  Platelets ≥ 80,000/mm^3

          -  Chemistry laboratory results of:

               -  Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and direct
                  bilirubin

               -  Antinuclear antibody (ANA) ≤ 1:320

               -  Fasting Glucose 70-140 mg/dL Note: If glucose levels are between 116-140 mg/dL or
                  an individual has diabetes, glycosylated hemoglobin [HbA1C] must be ≤ 8.5%

        EXCLUSION CRITERIA:

          -  Previous hepatitis C treatment

          -  Pregnant women or partners of pregnant women

          -  Patients or partners of patients who intend to become pregnant any time during the 48
             weeks

          -  Women who are breastfeeding

          -  Individuals with liver disease not caused by hepatitis C

          -  Individuals infected with the hepatitis B virus and/or human immunodeficiency virus
             (HIV)

          -  Patients with a history of liver cancer (hepatocellular carcinoma)

          -  Known blood disorders such as hemoglobinopathy, coagulopathy, or glucose-6-phosphate
             dehydrogenase [G6PD] deficiency

          -  Body organ transplant

          -  Any known or suspected cancer within the past 5 years

          -  Individuals who currently use epoetin [EPO], granulocyte colony stimulating factor
             [G-CSF] and/or granulocyte monocyte colony stimulating factor [GM-CSF]

          -  Those having a history of or active clinical gout

          -  Individuals who have chronic pulmonary disease

          -  Individuals who have a medical condition that would likely require systemic steroids

          -  Those with a history of central nervous system (CNS trauma) or seizure disorders

          -  Current or previous use of lithium or antipsychotic drugs

          -  Individuals who currently have or show signs of moderate to severe depression or
             history of significant psychiatric disorders

          -  Patients with clinically significant electrocardiogram (ECG) abnormalities

          -  Individuals with serious heart problems such as those who have had a heart attack,
             uncontrolled high blood pressure, or other heart problems

          -  Patients that weigh &gt; 231-275 pounds (105-125 kg) AND have a body mass index (BMI) &gt;
             30 AND have 3 or more of the risk factors below: (a) Strong family history of coronary
             heart disease (CHD) which includes 2 or more first-degree relatives with CHD or family
             history of early CHD at age &lt; 55 for male relatives or &lt; 65 for female relatives (b)
             Individuals with abnormal total cholesterol and/or sub fractions (uncontrolled
             hypercholesterolemia) (c) Diabetes (d) Hypertension (e) Smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027.</citation>
    <PMID>19625712</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2004</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <results_first_submitted>November 3, 2008</results_first_submitted>
  <results_first_submitted_qc>September 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 30, 2009</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrolled 4469 subjects; Randomized 3083; Treated 3070</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PegIntron 1.5 ug/kg/wk Plus REBETOL</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
        </group>
        <group group_id="P2">
          <title>PegIntron 1.0 ug/kg/wk Plus REBETOL</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
        </group>
        <group group_id="P3">
          <title>PEGASYS 180 ug/wk Plus COPEGUS</title>
          <description>PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1019"/>
                <participants group_id="P2" count="1016"/>
                <participants group_id="P3" count="1035"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="517">Patients who discontinued treatment but continued in study are considered Not Completed</participants>
                <participants group_id="P2" count="470">Patients who discontinued treatment but continued in study are considered Not Completed</participants>
                <participants group_id="P3" count="579">Patients who discontinued treatment but continued in study are considered Not Completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
                <participants group_id="P2" count="546"/>
                <participants group_id="P3" count="456"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="136"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="357"/>
                <participants group_id="P3" count="211"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PegIntron 1.5 ug/kg/wk Plus REBETOL</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
        </group>
        <group group_id="B2">
          <title>PegIntron 1.0 ug/kg/wk Plus REBETOL</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
        </group>
        <group group_id="B3">
          <title>PEGASYS 180 ug/wk Plus COPEGUS</title>
          <description>PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1019"/>
            <count group_id="B2" value="1016"/>
            <count group_id="B3" value="1035"/>
            <count group_id="B4" value="3070"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.5" spread="7.8"/>
                    <measurement group_id="B2" value="47.5" spread="8.1"/>
                    <measurement group_id="B3" value="47.6" spread="8.2"/>
                    <measurement group_id="B4" value="47.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="406"/>
                    <measurement group_id="B2" value="409"/>
                    <measurement group_id="B3" value="422"/>
                    <measurement group_id="B4" value="1237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="613"/>
                    <measurement group_id="B2" value="607"/>
                    <measurement group_id="B3" value="613"/>
                    <measurement group_id="B4" value="1833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response (SVR) Rate</title>
        <description>SVR rate is the percentage of participants with undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at the end of the 24-week post-treatment follow-up.</description>
        <time_frame>Assessed at the end of a 24-week post-treatment follow-up</time_frame>
        <population>Intent-to-Treat [ITT] Population defined as subjects who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>PegIntron 1.5 ug/kg/wk Plus REBETOL</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
          <group group_id="O2">
            <title>PegIntron 1.0 ug/kg/wk Plus REBETOL</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEGASYS 180 ug/wk Plus COPEGUS</title>
            <description>PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (SVR) Rate</title>
          <description>SVR rate is the percentage of participants with undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at the end of the 24-week post-treatment follow-up.</description>
          <population>Intent-to-Treat [ITT] Population defined as subjects who received at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1019"/>
                <count group_id="O2" value="1016"/>
                <count group_id="O3" value="1035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8"/>
                    <measurement group_id="O2" value="38.0"/>
                    <measurement group_id="O3" value="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.567</p_value>
            <p_value_desc>Holm’s method for multiplicity adjustment was to be used to control the overall Type I error rate at α = 0.05. However, since there was no significant difference in the overall SVR rates between the three groups, no Type-1 error adjustment was made.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The p-value is based on the logistic regression model that includes treatment and baseline stratification factors (viral load and race).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>The odds ratio is based on the logistic regression model that includes treatment and baseline stratification factors: viral load (≤600,000 IU/mL vs &gt;600,000 IU/mL) and race (Black vs non-Black).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.195</p_value>
            <p_value_desc>Holm’s method for multiplicity adjustment was to be used to control the overall Type I error rate at α = 0.05. However, since there was no significant difference in the overall SVR rates between the three groups, no Type-1 error adjustment was made.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The p-value is based on the logistic regression model that includes treatment and baseline stratification factors (viral load and race).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>The odds ratio is based on the logistic regression model that includes treatment and baseline stratification factors: viral load (≤600,000 IU/mL vs &gt;600,000 IU/mL) and race (Black vs non-Black).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Log Viral Load at Treatment Week 4</title>
        <description>The difference between viral load levels in the blood at the start of the study and Treatment Week 4, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.</description>
        <time_frame>Assessed at Baseline and Treatment Week 4</time_frame>
        <population>ITT Population defined as subjects who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>PegIntron 1.5 ug/kg/wk Plus REBETOL</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
          <group group_id="O2">
            <title>PegIntron 1.0 ug/kg/wk Plus REBETOL</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEGASYS 180 ug/wk Plus COPEGUS</title>
            <description>PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Log Viral Load at Treatment Week 4</title>
          <description>The difference between viral load levels in the blood at the start of the study and Treatment Week 4, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.</description>
          <population>ITT Population defined as subjects who received at least one dose of study medication</population>
          <units>Log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1019"/>
                <count group_id="O2" value="1016"/>
                <count group_id="O3" value="1035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="1.50"/>
                    <measurement group_id="O2" value="-2.02" spread="1.42"/>
                    <measurement group_id="O3" value="-2.45" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response Rate at Treatment Week 12</title>
        <description>Percentage of participants with undetectable hepatitis C RNA (HCV-RNA) at Treatment Week 12</description>
        <time_frame>Assessed at Treatment Week 12</time_frame>
        <population>ITT Population defined as subjects who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>PegIntron 1.5 ug/kg/wk Plus REBETOL</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
          <group group_id="O2">
            <title>PegIntron 1.0 ug/kg/wk Plus REBETOL</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEGASYS 180 ug/wk Plus COPEGUS</title>
            <description>PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response Rate at Treatment Week 12</title>
          <description>Percentage of participants with undetectable hepatitis C RNA (HCV-RNA) at Treatment Week 12</description>
          <population>ITT Population defined as subjects who received at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1019"/>
                <count group_id="O2" value="1016"/>
                <count group_id="O3" value="1035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9"/>
                    <measurement group_id="O2" value="36.0"/>
                    <measurement group_id="O3" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>39.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>36.9</ci_lower_limit>
            <ci_upper_limit>42.9</ci_upper_limit>
            <estimate_desc>Percentage of participants with undetectable HCV-RNA at Treatment Week 12</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>36.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>33.1</ci_lower_limit>
            <ci_upper_limit>39.0</ci_upper_limit>
            <estimate_desc>Percentage of participants with undetectable HCV-RNA at Treatment Week 12</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>45.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>42.0</ci_lower_limit>
            <ci_upper_limit>48.1</ci_upper_limit>
            <estimate_desc>Percentage of participants with undetectable HCV-RNA at Treatment Week 12</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Log Viral Load at Treatment Week 2</title>
        <description>The difference between viral load levels in the blood at the start of the study and Treatment Week 2, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.</description>
        <time_frame>Assessed at Baseline and Treatment Week 2</time_frame>
        <population>ITT Population defined as subjects who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>PegIntron 1.5 ug/kg/wk Plus REBETOL</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
          <group group_id="O2">
            <title>PegIntron 1.0 ug/kg/wk Plus REBETOL</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEGASYS 180 ug/wk Plus COPEGUS</title>
            <description>PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Log Viral Load at Treatment Week 2</title>
          <description>The difference between viral load levels in the blood at the start of the study and Treatment Week 2, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.</description>
          <population>ITT Population defined as subjects who received at least one dose of study medication</population>
          <units>Log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1019"/>
                <count group_id="O2" value="1016"/>
                <count group_id="O3" value="1035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="1.20"/>
                    <measurement group_id="O2" value="-1.30" spread="1.12"/>
                    <measurement group_id="O3" value="-1.60" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PegIntron 1.5 ug/kg/wk Plus REBETOL</title>
        </group>
        <group group_id="E2">
          <title>PegIntron 1.0 ug/kg/wk Plus REBETOL</title>
        </group>
        <group group_id="E3">
          <title>PEGASYS 180 ug/wk Plus COPEGUS</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1019"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="1016"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>APLASTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>THROMBOTIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>WOLFF-PARKINSON-WHITE SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>HEARING IMPAIRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MACULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PAPILLOEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1016"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PANCREATIC CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PANCREATIC ENLARGEMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PANCREATIC MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SALIVARY DUCT OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1016"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1019"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1016"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DRUG WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FACE OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BILIARY DYSKINESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PORTAL HYPERTENSIVE GASTROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SARCOIDOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL WALL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ANOGENITAL WARTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1016"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BLASTOMYCOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1016"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HERPES OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INFECTIVE TENOSYNOVITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INJECTION SITE CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MENINGITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1016"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SEPSIS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SKIN INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BACK INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HEPATIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HUMAN BITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>JAW FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LUNG INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL BILE LEAK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SCAPULA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>THERAPEUTIC AGENT TOXICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>TOOTH FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>TRAUMATIC BRAIN INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GRIP STRENGTH DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>JOINT INSTABILITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>WEIGHT BEARING DIFFICULTY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACOUSTIC NEUROMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HAEMANGIOMA OF LIVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MALIGNANT NEOPLASM OF AMPULLA OF VATER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>OVARIAN ADENOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AKATHISIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ANOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FACIAL PALSY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PARAPLEGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PERONEAL NERVE PALSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SPINAL CORD INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SYNCOPE VASOVAGAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PSYCHOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>AFFECTIVE DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ANGER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DEPENDENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="1019"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DRUG ABUSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DRUG DEPENDENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, AUDITORY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HOMICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PARANOIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="1019"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1016"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RENAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>CERVICAL DYSPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RECTOCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>VAGINAL PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PULMONARY SARCOIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA MULTIFORME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>PHYSICAL ASSAULT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CYSTOPEXY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYSTERECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RECTOCELE REPAIR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SALPINGO-OOPHORECTOMY UNILATERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SPINAL FUSION SURGERY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1019"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1019"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1016"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="996" subjects_at_risk="1019"/>
                <counts group_id="E2" subjects_affected="1000" subjects_at_risk="1016"/>
                <counts group_id="E3" subjects_affected="1018" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="555" subjects_affected="344" subjects_at_risk="1019"/>
                <counts group_id="E2" events="442" subjects_affected="291" subjects_at_risk="1016"/>
                <counts group_id="E3" events="556" subjects_affected="348" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="153" subjects_affected="95" subjects_at_risk="1019"/>
                <counts group_id="E2" events="109" subjects_affected="69" subjects_at_risk="1016"/>
                <counts group_id="E3" events="206" subjects_affected="106" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="466" subjects_affected="263" subjects_at_risk="1019"/>
                <counts group_id="E2" events="300" subjects_affected="188" subjects_at_risk="1016"/>
                <counts group_id="E3" events="670" subjects_affected="325" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="1019"/>
                <counts group_id="E2" events="45" subjects_affected="24" subjects_at_risk="1016"/>
                <counts group_id="E3" events="111" subjects_affected="64" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="61" subjects_affected="56" subjects_at_risk="1019"/>
                <counts group_id="E2" events="42" subjects_affected="39" subjects_at_risk="1016"/>
                <counts group_id="E3" events="51" subjects_affected="48" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="52" subjects_affected="46" subjects_at_risk="1019"/>
                <counts group_id="E2" events="69" subjects_affected="62" subjects_at_risk="1016"/>
                <counts group_id="E3" events="76" subjects_affected="74" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="59" subjects_affected="47" subjects_at_risk="1019"/>
                <counts group_id="E2" events="60" subjects_affected="53" subjects_at_risk="1016"/>
                <counts group_id="E3" events="70" subjects_affected="61" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="60" subjects_affected="51" subjects_at_risk="1019"/>
                <counts group_id="E2" events="55" subjects_affected="50" subjects_at_risk="1016"/>
                <counts group_id="E3" events="69" subjects_affected="54" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="85" subjects_affected="77" subjects_at_risk="1019"/>
                <counts group_id="E2" events="89" subjects_affected="83" subjects_at_risk="1016"/>
                <counts group_id="E3" events="68" subjects_affected="63" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="221" subjects_affected="170" subjects_at_risk="1019"/>
                <counts group_id="E2" events="230" subjects_affected="193" subjects_at_risk="1016"/>
                <counts group_id="E3" events="207" subjects_affected="173" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="60" subjects_affected="58" subjects_at_risk="1019"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="1016"/>
                <counts group_id="E3" events="52" subjects_affected="50" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="62" subjects_affected="60" subjects_at_risk="1019"/>
                <counts group_id="E2" events="72" subjects_affected="62" subjects_at_risk="1016"/>
                <counts group_id="E3" events="78" subjects_affected="69" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="517" subjects_affected="433" subjects_at_risk="1019"/>
                <counts group_id="E2" events="462" subjects_affected="377" subjects_at_risk="1016"/>
                <counts group_id="E3" events="434" subjects_affected="375" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="190" subjects_affected="150" subjects_at_risk="1019"/>
                <counts group_id="E2" events="149" subjects_affected="122" subjects_at_risk="1016"/>
                <counts group_id="E3" events="141" subjects_affected="119" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="57" subjects_affected="51" subjects_at_risk="1019"/>
                <counts group_id="E2" events="48" subjects_affected="44" subjects_at_risk="1016"/>
                <counts group_id="E3" events="43" subjects_affected="41" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="428" subjects_affected="397" subjects_at_risk="1019"/>
                <counts group_id="E2" events="421" subjects_affected="365" subjects_at_risk="1016"/>
                <counts group_id="E3" events="266" subjects_affected="243" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="798" subjects_affected="672" subjects_at_risk="1019"/>
                <counts group_id="E2" events="802" subjects_affected="676" subjects_at_risk="1016"/>
                <counts group_id="E3" events="809" subjects_affected="656" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="203" subjects_affected="164" subjects_at_risk="1019"/>
                <counts group_id="E2" events="175" subjects_affected="154" subjects_at_risk="1016"/>
                <counts group_id="E3" events="182" subjects_affected="160" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="172" subjects_affected="166" subjects_at_risk="1019"/>
                <counts group_id="E2" events="197" subjects_affected="178" subjects_at_risk="1016"/>
                <counts group_id="E3" events="125" subjects_affected="123" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" events="118" subjects_affected="102" subjects_at_risk="1019"/>
                <counts group_id="E2" events="116" subjects_affected="112" subjects_at_risk="1016"/>
                <counts group_id="E3" events="62" subjects_affected="58" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="317" subjects_affected="256" subjects_at_risk="1019"/>
                <counts group_id="E2" events="319" subjects_affected="262" subjects_at_risk="1016"/>
                <counts group_id="E3" events="314" subjects_affected="262" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="156" subjects_affected="126" subjects_at_risk="1019"/>
                <counts group_id="E2" events="168" subjects_affected="138" subjects_at_risk="1016"/>
                <counts group_id="E3" events="124" subjects_affected="100" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="417" subjects_affected="356" subjects_at_risk="1019"/>
                <counts group_id="E2" events="381" subjects_affected="331" subjects_at_risk="1016"/>
                <counts group_id="E3" events="264" subjects_affected="237" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="1019"/>
                <counts group_id="E2" events="39" subjects_affected="32" subjects_at_risk="1016"/>
                <counts group_id="E3" events="66" subjects_affected="60" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="72" subjects_affected="59" subjects_at_risk="1019"/>
                <counts group_id="E2" events="53" subjects_affected="43" subjects_at_risk="1016"/>
                <counts group_id="E3" events="90" subjects_affected="72" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="164" subjects_affected="138" subjects_at_risk="1019"/>
                <counts group_id="E2" events="122" subjects_affected="105" subjects_at_risk="1016"/>
                <counts group_id="E3" events="116" subjects_affected="102" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="131" subjects_affected="121" subjects_at_risk="1019"/>
                <counts group_id="E2" events="100" subjects_affected="96" subjects_at_risk="1016"/>
                <counts group_id="E3" events="81" subjects_affected="76" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="197" subjects_affected="184" subjects_at_risk="1019"/>
                <counts group_id="E2" events="167" subjects_affected="159" subjects_at_risk="1016"/>
                <counts group_id="E3" events="152" subjects_affected="142" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="296" subjects_affected="238" subjects_at_risk="1019"/>
                <counts group_id="E2" events="294" subjects_affected="237" subjects_at_risk="1016"/>
                <counts group_id="E3" events="307" subjects_affected="250" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="118" subjects_affected="105" subjects_at_risk="1019"/>
                <counts group_id="E2" events="125" subjects_affected="106" subjects_at_risk="1016"/>
                <counts group_id="E3" events="136" subjects_affected="120" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="64" subjects_affected="53" subjects_at_risk="1019"/>
                <counts group_id="E2" events="63" subjects_affected="51" subjects_at_risk="1016"/>
                <counts group_id="E3" events="88" subjects_affected="72" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="309" subjects_affected="274" subjects_at_risk="1019"/>
                <counts group_id="E2" events="305" subjects_affected="270" subjects_at_risk="1016"/>
                <counts group_id="E3" events="263" subjects_affected="233" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="55" subjects_affected="52" subjects_at_risk="1019"/>
                <counts group_id="E2" events="66" subjects_affected="56" subjects_at_risk="1016"/>
                <counts group_id="E3" events="105" subjects_affected="74" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="81" subjects_affected="72" subjects_at_risk="1019"/>
                <counts group_id="E2" events="60" subjects_affected="53" subjects_at_risk="1016"/>
                <counts group_id="E3" events="81" subjects_affected="71" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="218" subjects_affected="172" subjects_at_risk="1019"/>
                <counts group_id="E2" events="194" subjects_affected="154" subjects_at_risk="1016"/>
                <counts group_id="E3" events="171" subjects_affected="145" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="88" subjects_affected="80" subjects_at_risk="1019"/>
                <counts group_id="E2" events="76" subjects_affected="73" subjects_at_risk="1016"/>
                <counts group_id="E3" events="70" subjects_affected="66" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="646" subjects_affected="508" subjects_at_risk="1019"/>
                <counts group_id="E2" events="609" subjects_affected="486" subjects_at_risk="1016"/>
                <counts group_id="E3" events="559" subjects_affected="438" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="142" subjects_affected="114" subjects_at_risk="1019"/>
                <counts group_id="E2" events="143" subjects_affected="117" subjects_at_risk="1016"/>
                <counts group_id="E3" events="125" subjects_affected="112" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="351" subjects_affected="259" subjects_at_risk="1019"/>
                <counts group_id="E2" events="263" subjects_affected="197" subjects_at_risk="1016"/>
                <counts group_id="E3" events="257" subjects_affected="215" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="482" subjects_affected="401" subjects_at_risk="1019"/>
                <counts group_id="E2" events="460" subjects_affected="389" subjects_at_risk="1016"/>
                <counts group_id="E3" events="500" subjects_affected="428" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="202" subjects_affected="167" subjects_at_risk="1019"/>
                <counts group_id="E2" events="223" subjects_affected="183" subjects_at_risk="1016"/>
                <counts group_id="E3" events="256" subjects_affected="210" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="200" subjects_affected="176" subjects_at_risk="1019"/>
                <counts group_id="E2" events="201" subjects_affected="173" subjects_at_risk="1016"/>
                <counts group_id="E3" events="194" subjects_affected="172" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="58" subjects_affected="55" subjects_at_risk="1019"/>
                <counts group_id="E2" events="59" subjects_affected="55" subjects_at_risk="1016"/>
                <counts group_id="E3" events="81" subjects_affected="75" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="69" subjects_affected="63" subjects_at_risk="1019"/>
                <counts group_id="E2" events="73" subjects_affected="67" subjects_at_risk="1016"/>
                <counts group_id="E3" events="86" subjects_affected="76" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="249" subjects_affected="233" subjects_at_risk="1019"/>
                <counts group_id="E2" events="211" subjects_affected="205" subjects_at_risk="1016"/>
                <counts group_id="E3" events="178" subjects_affected="176" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="134" subjects_affected="122" subjects_at_risk="1019"/>
                <counts group_id="E2" events="125" subjects_affected="117" subjects_at_risk="1016"/>
                <counts group_id="E3" events="162" subjects_affected="137" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="194" subjects_affected="163" subjects_at_risk="1019"/>
                <counts group_id="E2" events="168" subjects_affected="138" subjects_at_risk="1016"/>
                <counts group_id="E3" events="222" subjects_affected="182" subjects_at_risk="1035"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="289" subjects_affected="225" subjects_at_risk="1019"/>
                <counts group_id="E2" events="280" subjects_affected="223" subjects_at_risk="1016"/>
                <counts group_id="E3" events="429" subjects_affected="290" subjects_at_risk="1035"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

